This study is examining a treatment called ritlecitinib for nonsegmental vitiligo, a skin condition causing white patches. The study lasts for 52 weeks (1 year) and tests the safety and effects of the treatment. It is a Phase 3 study, meaning it's in the final stage before potential approval. Participants must have vitiligo for at least 3 months, affecting 4%-60% of their body, including at least 0.5% of their face. They should have either active (new spots) or stable (no new spots) vitiligo. Participants must stop other vitiligo treatments during the study.

• The study lasts for one year with regular check-ups.
• Participants must be willing to stop other vitiligo treatments.
• Eligible for ages 12 and up, with specific skin and health conditions.

Not everyone can join. Exclusions include certain skin diseases, infections, or psychiatric conditions. Safety is important, so previous severe allergies or certain health conditions are considered. Participants and their health will be carefully monitored to ensure safety throughout the study.